knowledge -WSS

knowledge

author：knowledge 2025-09-07 06:42:27 - browse：49

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla Giannis Papanikos/AP

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen, a maker of a hot category of oncology medicines called antibody-drug conjugates. Pfizer’s shares have slumped another 9% so far this year. On Thursday, executives are holding an investor briefing to try to convince shareholders that its bet will pay off.

In an interview with STAT, Pfizer CEO Albert Bourla was insistent that the deal’s potential is being missed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The aspartame in Diet Coke probably isn’t giving you cancer

entertainment

WSS

Biden targets hefty hospital 'facility fees' that often surprise patients

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

The aspartame in Diet Coke probably isn’t giving you cancer

Eisai exec who led development of Alzheimer’s drug to retire

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

focus

knowledge

leisure time

Peter Hotez and the public health issue of online harassment

ACA's risk program benefits Blue Cross Blue Shield insurers

The cancer drug shortage isn’t new — and neither are the solutions

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

Hollywood unions extend contract negotiations for actors

Biotech investment managers search for lucrative opportunities

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Medicare proposal to cover medical devices draws a mixed reaction

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

explore

Pfizer, Moderna say biotech, pharma drug development is a sprint

Medicare Advantage insurers pressure Biden for bigger payments

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Yancopoulos of Regeneron works to expand Dupixent success

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Pandemic and All Hazards Preparedness Act needs lean update

hotspot

focus

entertainment

entertainment